Giulia Siravegna

20.8k total citations · 2 hit papers
42 papers, 3.3k citations indexed

About

Giulia Siravegna is a scholar working on Cancer Research, Pulmonary and Respiratory Medicine and Oncology. According to data from OpenAlex, Giulia Siravegna has authored 42 papers receiving a total of 3.3k indexed citations (citations by other indexed papers that have themselves been cited), including 29 papers in Cancer Research, 27 papers in Pulmonary and Respiratory Medicine and 25 papers in Oncology. Recurrent topics in Giulia Siravegna's work include Cancer Genomics and Diagnostics (28 papers), Colorectal Cancer Treatments and Studies (20 papers) and Lung Cancer Treatments and Mutations (17 papers). Giulia Siravegna is often cited by papers focused on Cancer Genomics and Diagnostics (28 papers), Colorectal Cancer Treatments and Studies (20 papers) and Lung Cancer Treatments and Mutations (17 papers). Giulia Siravegna collaborates with scholars based in Italy, United States and Spain. Giulia Siravegna's co-authors include Alberto Bardelli, Silvia Marsoni, Salvatore Siena, Benedetta Mussolin, Ryan B. Corcoran, Andrea Sartore‐Bianchi, Federica Di Nicolantonio, Tiziana Venesio, Caroline Dive and Leticia De Mattos‐Arruda and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and Clinical Cancer Research.

In The Last Decade

Giulia Siravegna

42 papers receiving 3.3k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Integrating liquid biopsies into the management of cancer

2017 1.4k citations Giulia Siravegna, Silvia Marsoni et al. profile →
Clinical Acquired Resistance to KRASG12C Inhibition through a Novel KRAS Switch-II Pocket Mutation and Polyclonal Alterations Converging on RAS–MAPK Reactivation

2021 302 citations Noritaka Tanaka, W. Marston Linehan et al. Cancer Discovery profile →

Peers

Countries citing papers authored by Giulia Siravegna

Since Specialization

Citations

This map shows the geographic impact of Giulia Siravegna's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Giulia Siravegna with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Giulia Siravegna more than expected).

Fields of papers citing papers by Giulia Siravegna

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Giulia Siravegna. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Giulia Siravegna. The network helps show where Giulia Siravegna may publish in the future.

Co-authorship network of co-authors of Giulia Siravegna

This figure shows the co-authorship network connecting the top 25 collaborators of Giulia Siravegna. A scholar is included among the top collaborators of Giulia Siravegna based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Giulia Siravegna. Giulia Siravegna is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Landscape of Clinical Resistance Mechanisms to FGFR Inhibitors in FGFR2-Altered Cholangiocarcinoma 2023 ·Clinical Cancer Research ·(unknown), Haley Ellis, Giulia Siravegna, Alexa Michel, (unknown), Ferran Fece de la Cruz, Eranga R. Balasooriya, Yuanli Zhen, Vanessa S. Silveira, (unknown), Ryan B. Corcoran, Nabeel Bardeesy	38
2	Patient-Reported Outcomes, Tumor Markers, and Survival Outcomes in Advanced GI Cancer 2023 ·JAMA Network Open ·(unknown), Anurag Saraf, Islam Baiev, (unknown), Emily E. Van Seventer, Amirkasra Mojtahed, Jill N. Allen, Jeffrey W. Clark, Lawrence S. Blaszkowsky, Bruce J. Giantonio, Colin D. Weekes, Samuel J. Klempner, Joseph W. Franses, Eric Roeland, Lipika Goyal, Giulia Siravegna, Nora Horick, Ryan B. Corcoran, Ryan David Nipp, Aparna R. Parikh	5
3	Clinical Acquired Resistance to KRASG12C Inhibition through a Novel KRAS Switch-II Pocket Mutation and Polyclonal Alterations Converging on RAS–MAPK Reactivation breakdown → 2021 ·Cancer Discovery ·Noritaka Tanaka, W. Marston Linehan, Chendi Li, Meagan B. Ryan, Junbing Zhang, Lesli A. Kiedrowski, Alexa Michel, Mohammed U. Syed, (unknown), Mustafa Sakhi, Islam Baiev, Dejan Juric, Justin F. Gainor, Samuel J. Klempner, Jochen K. Lennerz, Giulia Siravegna, Liron Bar‐Peled, Aaron N. Hata, Rebecca S. Heist, Ryan B. Corcoran	302
4	How to use liquid biopsies to treat patients with cancer 2021 ·ESMO Open ·Leticia De Mattos‐Arruda, Giulia Siravegna	50
5	Genome-wide Copy-number Alterations in Circulating Tumor DNA as a Novel Biomarker for Patients with High-grade Serous Ovarian Cancer 2020 ·Clinical Cancer Research ·Lara Paracchini, Luca Beltrame, Tommaso Grassi, (unknown), Robert Fruscio, Fabio Landoni, Davide Ippolito, Martina Delle Marchette, (unknown), (unknown), (unknown), Chiara Romualdi, Maurizio D’Incalci, Giulia Siravegna, Sergio Marchini	38
6	419P Minimal residual disease (MRD) detection in colorectal cancer (CRC) using a plasma-only integrated genomic and epigenomic circulating tumor DNA (ctDNA) assay 2020 ·Annals of Oncology ·Aparna R. Parikh, (unknown), Genevieve M. Boland, Giulia Siravegna, Anna Hartwig, Ariel Jaimovich, Victoria M. Raymond, AmirAli Talasaz, Ryan B. Corcoran	1
7	A Genomic Analysis Workflow for Colorectal Cancer Precision Oncology 2019 ·Clinical Colorectal Cancer ·Giorgio Corti, Alice Bartolini, Giovanni Crisafulli, Luca Novara, Giuseppe Rospo, Monica Montone, (unknown), Benedetta Mussolin, Michela Buscarino, Claudio Isella, Ludovic Barault, Giulia Siravegna, Salvatore Siena, Silvia Marsoni, Federica Di Nicolantonio, Enzo Médico, Alberto Bardelli	19
8	Plasma HER2 ( ERBB2 ) Copy Number Predicts Response to HER2-targeted Therapy in Metastatic Colorectal Cancer 2019 ·Clinical Cancer Research ·Giulia Siravegna, Andrea Sartore‐Bianchi, Rebecca J. Nagy, Kanwal Raghav, Justin I. Odegaard, Richard B. Lanman, Livio Trusolino, Silvia Marsoni, Salvatore Siena, Alberto Bardelli	102
9	How liquid biopsies can change clinical practice in oncology 2019 ·Annals of Oncology ·Giulia Siravegna, Benedetta Mussolin, Tiziana Venesio, Silvia Marsoni, Joan Seoane, Caroline Dive, Nickolas Papadopoulos, Scott Kopetz, Ryan B. Corcoran, Lillian L. Siu, Alberto Bardelli	243
10	Whole exome sequencing analysis of urine trans-renal tumour DNA in metastatic colorectal cancer patients 2019 ·ESMO Open ·Giovanni Crisafulli, Benedetta Mussolin, Andrea Cassingena, Monica Montone, Alice Bartolini, Ludovic Barault, Antonia Martinetti, Federica Morano, Filippo Pietrantonio, Andrea Sartore‐Bianchi, Salvatore Siena, Federica Di Nicolantonio, Silvia Marsoni, Alberto Bardelli, Giulia Siravegna	24
11	Retreatment with anti-EGFR monoclonal antibodies in metastatic colorectal cancer: Systematic review of different strategies 2018 ·Cancer Treatment Reviews ·Gianluca Mauri, Elio Gregory Pizzutilo, Alessio Amatu, Katia Bencardino, Laura Palmeri, Erica Bonazzina, Federica Tosi, G Stella, Giovanni Burrafato, Francesco Scaglione, Silvia Marsoni, Giulia Siravegna, Alberto Bardelli, Salvatore Siena, Andrea Sartore‐Bianchi	65
12	Liquid Biopsies for Monitoring Temporal Genomic Heterogeneity in Breast and Colon Cancers 2017 ·Pathobiology ·Tiziana Venesio, Giulia Siravegna, Alberto Bardelli, Anna Sapino	36
13	Systematic liquid biopsy identifies novel and heterogeneous mechanisms of acquired resistance in gastrointestinal (GI) cancer patients 2017 ·Annals of Oncology ·Aparna Parikh, Lipika Goyal, Mehlika Hazar-Rethinam, Giulia Siravegna, Lawrence S. Blaszkowsky, Mariangela Russo, (unknown), Brandon Nadres, Heather A. Shahzade, Jeffrey W. Clark, Jill N. Allen, (unknown), David P. Ryan, Janet E. Murphy, Alberto Bardelli, Andrew X. Zhu, Theodore S. Hong, Ryan B. Corcoran	5
14	Genotyping circulating tumor DNA identifies metastatic colorectal cancer (mCRC) patients highly sensitive to Sym004 2017 ·Annals of Oncology ·(unknown), Alberto Bardelli, Thomas T. Poulsen, Rodrigo Dienstmann, Michael Kragh, Scott Kopetz, Klaus Koefoed, Fortunato Ciardiello, (unknown), Joana Vidal, Jenifer Clausell-Tormos, Giulia Siravegna, Trine Lindsted, Mikkel W. Pedersen, Giuseppe Rospo, (unknown), Paul I. Nadler, Ivan D. Horak, Josep Tabernero	1
15	Tracking aCAD-ALK gene rearrangement in urine and blood of a colorectal cancer patient treated with an ALK inhibitor 2017 ·Annals of Oncology ·Giulia Siravegna, Andrea Sartore‐Bianchi, Benedetta Mussolin, Andrea Cassingena, Alessio Amatu, Luca Novara, Michela Buscarino, Giorgio Corti, Giovanni Crisafulli, Alice Bartolini, Federica Tosi, Mark G. Erlander, Federica Di Nicolantonio, Salvatore Siena, Alberto Bardelli	31
16	Parallel Evaluation of Circulating Tumor DNA and Circulating Tumor Cells in Metastatic Colorectal Cancer 2017 ·Clinical Colorectal Cancer ·Giovanni Germano, Gianluca Mauri, Giulia Siravegna, Caroline Dive, Jackie Pierce, Federica Di Nicolantonio, Maurizio D’Incalci, Alberto Bardelli, Salvatore Siena, Andrea Sartore‐Bianchi	39
17	MET-Driven Resistance to Dual EGFR and BRAF Blockade May Be Overcome by Switching from EGFR to MET Inhibition in BRAF -Mutated Colorectal Cancer 2016 ·Cancer Discovery ·Filippo Pietrantonio, Daniele Oddo, Annunziata Gloghini, Emanuele Valtorta, Rosa Berenato, Ludovic Barault, Marta Caporale, Adele Busico, Federica Morano, Ambra V. Gualeni, Alessandra Alessi, Giulia Siravegna, Federica Perrone, Maria Di Bartolomeo, Alberto Bardelli, Filippo de Braud, Federica Di Nicolantonio	78
18	Clonal evolution and KRAS-MET coamplification during secondary resistance to EGFR-targeted therapy in metastatic colorectal cancer 2016 ·ESMO Open ·Andrea Sartore‐Bianchi, Emanuele Valtorta, Alessio Amatu, Silvio Veronese, Calogero Lauricella, Erica Bonazzina, Giulia Siravegna, Mauro Truini, Alberto Bardelli, Salvatore Siena	3
19	Molecular Heterogeneity and Receptor Coamplification Drive Resistance to Targeted Therapy in MET -Amplified Esophagogastric Cancer 2015 ·Cancer Discovery ·Eunice L. Kwak, Leanne G. Ahronian, Giulia Siravegna, Benedetta Mussolin, Darrell R. Borger, Jason T. Godfrey, Nicholas A. Jessop, Jeffrey W. Clark, Lawrence S. Blaszkowsky, David P. Ryan, Jochen K. Lennerz, A. John Iafrate, Alberto Bardelli, Theodore S. Hong, Ryan B. Corcoran	138
20	Blood circulating tumor DNA for non‐invasive genotyping of colon cancer patients 2015 ·Molecular Oncology ·Giulia Siravegna, Alberto Bardelli	45

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact